Firvanq will replace CutisPharma's FIRST-Vancomycin Unit-of-Use Compounding Kit. CutisPharma announced the availability of Firvanq (vancomycin HCl) for oral solution to treat Clostridium ...

WILMINGTON, Mass., April 2, 2018 /PRNewswire/ -- CutisPharma announced today the commercial launch of FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile ...

WILMINGTON, Mass., Jan. 29, 2018 /PRNewswire/ -- CutisPharma announced today that the US Food and Drug Administration (FDA) has approved FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the ...

The FDA on Monday granted approval to CutisPharma's drug Firvanq to treat Clostridium difficile-associated diarrhea and Staphylococcus aureus-associated intestinal inflammation (enterocolitis). Here ...

Vancomycin is indicated to treat enterocolitis caused by Staphylococcus aureus and antibiotic-associated pseudomembranous colitis caused by C. difficile. ANI Pharmaceuticals announced that the Food ...

BAUDETTE, Minn., Sept. 11, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Vancomycin HCl for Oral Solution, 250mg per 5mL (the generic equivalent ...

WILMINGTON — CutisPharma announced that the US Food and Drug Administration has approved FIRVANQ (vancomycin hydrochloride) for oral solution for the treatment of Clostridium difficile associated ...

Azurity Pharmaceuticals, Inc. — a pioneer drug company that markets its FDA-approved oral vancomycin hydrochloride solution, FIRVANQ® — has sued Edge Pharma, LLC, an outsourcing facility operating ...

The FDA on Monday granted approval to CutisPharma’s drug Firvanq to treat Clostridium difficile-associated diarrhea and Staphylococcus aureus-associated intestinal inflammation (enterocolitis). Here ...

BAUDETTE, Minn., June 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received FDA approval of its Prior Approval Supplement for Vancomycin ...